Global Aquaculture Vaccine Industry is forecasted to attain US$ 913.6 Million by 2033, according to FMI

Aquaculture Vaccine Industry
Aquaculture Vaccine Industry

The global aquaculture vaccines industry growth is worth US$ 406 Million as of now and is expected to reach US$ 913.6 Million by the year 2033 at a CAGR of 8.5% between 2023 and 2033. Surge in aquaculture is the factor majorly driving the aquaculture vaccines market. There is an ever-increasing demand for canned fish products, seafood, and aquaculture-oriented activities. It is a known fact that seafood is rich in nutrition and ends up creating a positive impact on human health.

Live vaccines comprise live viruses and bacteria with a comparatively lower severity in the fish species. As live vaccines do induce cell-mediated & humoral antibodies and mucosal immunity, the immunity of the fish gets boosted. Extensive research is being conducted on this count so that benefits like ease of culturing, cost-effective production, and clear genetic composition could be availed.

Get Your Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-16501

Immersion vaccines are reported to showcase superlative efficiency wherein mass vaccination is needed. They do receive stress on the fish and do minimize risks that the vaccination teams could be subject to. The basic functionality of immersion vaccines is that of bringing immune cells in the fills/skin of fish in touch with antigens; thereby stimulating the production of antibodies.

The aquaculture sector is exposed to prevalence of bacterial infections in the present scenario. Challenges like these are certainly prompting the fish farmers to significantly invest in incorporation of aquaculture vaccines. Besides, it has been observed that almost 70% of salmon consumed worldwide is farmed. Banning the sales of antibiotics is encouraging the fish farmers to go for high-value aquaculture vaccines.

At the same time, lack of awareness regarding importance of aquaculture vaccines in the under-developed economies is likely to hamper the aquaculture vaccines market in the near future.

Future Market Insights has entailed these facts with future perspectives in its latest market study entitled ‘Aquaculture Vaccines Market’. It has its dedicated team of analysts and consultants to execute using a bottom-up approach in its primary, secondary, and tertiary modes of research.

“With fish farming sector being compelled to churn out effective solutions for preventing viral and bacterial infections, the global aquaculture vaccines market is likely to witness consistence in the near future”, says an analyst from Future Market Insights.

Key Takeaways from Aquaculture Vaccines Market:

  • Europe holds more than 20% of the market share. This could be attributed to Norway being the largest exporter of salmon along with growing concerns regarding antimicrobial activities. The Norwegian Medicines Agency does make provision of specific guidelines and regulations related to the applications of autogenous vaccines. The European Commission has funded a huge-scale collaborative project under 7th Framework Programme for extending support to aquaculture industry.
  • North America holds a significant market share with the US witnessing a rising demand for safe and clean fish and other marine foodstuff.
  • The Asia-Pacific is expected to witness a sizable growth in aquaculture vaccines market going forward due to booming aquaculture vertical, thereby resulting in increase in production of various aquatic species like tilapia (especially in Japan).

In Case Of Any Queries, Don’t Hesitate To Contact Our Analyst! https://www.futuremarketinsights.com/ask-question/rep-gb-16501

Competitive Vaccines:

  • Virbac, in September 2020, did announce acquiring a series of tilapia vaccines from Ictyogroup (an animal health company specializing in research pertaining to biology). These two companies also inked a partnership agreement for Aqua Virbac division developing novel formulations and vaccines.
  • Barramundi Asia, in January 2020, did announce merging with Allergo Aqua with the objective of bringing fingerling research in-house. The method has thus helped in maintenance of long-term relationships.
  • Merck, in August 2020, completed acquisition of IdentiGEN to extend its line-up of livestock and aquaculture products.
  • Elanco, in December 2020, did move its headquarters to Indiana to complement its IPP (Innovation, Portfolio & Productivity) strategy and also establish a center of excellence for consolidation of future footprint.
  • CIBA, in April 2021, did launch Nodavac-R, which comes across as an injectable recombinant viral nervous necrosis (VNN) vaccine to avert vertical transmission in the brooders.
  • MSD Animal Health, in November 2019, did launch AQUAVAC Strep Sa-Si injectable and dip immersion vaccine against Streptococcis in the tilapia fish in LATAM.

What does the Report span?

  • The research study is based on product type (attenuated live vaccines, inactivated vaccines, subunit vaccines, DNA vaccines, and recombinant vaccines), by route of administration (oral, injected, and immersion & spray), and by type (viral, bacterial, and parasitic).
  • With rising demand for aquatic animal-derived food products, the global aquaculture vaccines market is bound to grow graciously in the near future.

Revolutionizing Customer Engagement: Learn from Our Customization Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16501

Key Companies Profiled:

  • GlaxoSmithKline plc
  • Merck & Co., Inc
  • Pfizer, Inc.
  • Sanofi SA
  • CSL Limited
  • Emergent BioSolutions, Inc.
  • Johnson & Johnson
  • AstraZeneca plc
  • Serum Institute of India Pvt. Ltd.
  • Bavarian Nordic A/S
  • Mitsubishi Tanabe Pharma Corporation
  • Daiichi Sankyo Company, Limited
  • Panacea Biotec, Ltd.
  • Biological E Limited
  • Bharat Biotech Ltd.
  • Novavax, Inc.

Market Segments Covered in Aquaculture Vaccines Industry Analysis:

Product Type Outlook:

  • Attenuated Live Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • DNA Vaccines
  • Recombinant Vaccines

Route of Administration:

  • Oral
  • Injected
  • Immersion & Spray

Regional Outlook:

  • Bacterial
  • Viral
  • Parasitic

Regional:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Gain Immediate Access to Detailed Market Insights: Purchase Now! https://www.futuremarketinsights.com/checkout/16501

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: 
sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these